<DOC>
	<DOCNO>NCT00528983</DOCNO>
	<brief_summary>The purpose study determine whether tablet form azacitidine take mouth safe . This Phase I study also look different dos different treatment schedule order well understand effect ( positive negative ) oral azacitidine body disease MDS , AML CMML .</brief_summary>
	<brief_title>Safety , Pharmacokinetics , Pharmacodynamics Oral Azacitidine Subjects With Myelodysplastic Syndromes , Chronic Myelomonocytic Leukemia Acute Myelogenous Leukemia</brief_title>
	<detailed_description>Optional Extension Phase ( OEP ) AZA PH US 2007 CL 005 study allow subject continue receive oral azacitidine stable disease demonstrate clinical benefit assess Investigator , consent participate , may enter OEP study ( current dos ) start next cycle . Subjects enter OEP discontinue Part 1 Part 2 protocol prescribe therapy AZA PH US 2007 CL 005 study . Subjects may continue receive oral azacitidine OEP meet criterion study discontinuation oral azacitidine become commercially available . Subjects discontinue OEP OEP discontinuation visit 28 day last dose study drug study withdrawal . Primary Objective OEP evaluate long term safety oral azacitidine .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>18 year old . Diagnosis low Int1 risk MDS Low platelet count , and/or low hemoglobin , and/or RBC transfusiondependent and/or platelet transfusiondependent ECOG Performance status 02 Standard safety inclusion serum creatinine , AST , ALT , bilirubin . Serum bicarbonate great equal 20 mEq/L . Use acceptable birth control . Signed , write informed consent . Diagnosis acute PML . Previous concurrent malignancy . Prior treatment azacitidine demethylating agent . Treatment anticancer therapy investigational drug within 21 day . Hypersensitivity azacitidine mannitol . Presence GI disease . Active , uncontrolled infection . Known Human Immunodeficiency Virus ( HIV ) Hepatitis C , know active viral Hepatitis B. Breastfeeding Pregnant females ; Presence serious illness , medical condition , medical history would likely interfere subject 's participation study interpretation result . Current congestive heart failure ( NY Heart Association Class IIIIV ) , unstable angina angina require surgical medical intervention within 6 month , myocardial infarct within 6 month , uncontrolled cardiac arrhythmia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Myelodysplastic Syndromes MDS</keyword>
	<keyword>Acute Myelogenous Leukemia AML</keyword>
	<keyword>Chronic Myelomonocytic Leukemia CMML</keyword>
</DOC>